Friday, 13 November 2026European Markets

NORBIT Stock Jumps By 28% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORBIT (Oslo Børs Benchmark Index_GI: NORBT.OL) rose by a staggering 28.11% in 21 sessions from kr43.4 to kr55.60 at 17:37 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 0.08% to kr1,227.29, after two consecutive sessions in a row of gains.

NORBIT's last close was kr54.60, 1.44% below its 52-week high of kr55.40.

About NORBIT

Norbit ASA provides technology products and solutions. It operates through Oceans, Connectivity, and Product Innovation and Realization segments. The company offers multibeam sonar systems, including integrated bathymetric systems, bathymetry systems, advanced monitoring systems for dredging, construction and renewables, forward looking wide area imaging, advanced imaging systems for obstacle avoidance/MCM, and above water laser products under the NORBIT WINGHEAD, NORBIT WBMS, NORBIT NORdredge, and NORBIT FLS names; customized cable assemblies, electromechanical box builds, and operational solutions; SeaCOP, a sensor integration platform and user interface common operational picture for emergency response; SECurus provides thermal and daylight stabilized camera solutions; SeaView, which offers thermal and daylight, pan, tilt, and zoom for environmental monitoring, and security and general surveillance; and SeaDarQ, a radar processing solution. It also provides sensing solutions for detecting threats at sea plus waterside security above and below the surface; FCL600, an underwater light solution for aquaculture industry; iData, which offers vehicle monitoring, telematics services, and fleet management for asset and vehicle management; and dedicated short-range communication technology for traffic system and vehicle application. In addition, the company offers research and development services, and contract manufacturing to industrial customers; and sells products based on proprietary technology, including special instrumentation n based on radar, radio frequency, and embedded signal processing technology. The company was founded in 1995 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, NORBIT has a trailing twelve months EPS of kr2.48.

PE Ratio

NORBIT has a trailing twelve months price to earnings ratio of 22.42. Meaning, the purchaser of the share is investing kr22.42 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.78%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

NORBIT's EBITDA is 2.68.

Moving Average

NORBIT's worth is way higher than its 50-day moving average of kr43.76 and way above its 200-day moving average of kr33.01.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 5, 2023, the estimated forward annual dividend rate is 0.7 and the estimated forward annual dividend yield is 1.27%.

More news about NORBIT (NORBT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com